.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers are currently launching the CAN-TRACK trial to evaluate medical cannabis driving performance. This investigation is essential because prescriptions for therapeutic THC are increasing for patients managing chronic pain, anxiety, and insomnia. However, most road safety laws prohibit driving with any detectable THC in the system. Consequently, this study will provide critical evidence to help balance patient clinical needs with public safety regulations.
Specifically, the first phase utilizes a semi-naturalistic cohort of 72 patients. These individuals suffer from physician-diagnosed chronic pain or insomnia. Moreover, they will complete repeated on-track driving tests before and after taking their standard prescribed doses. In contrast, the second phase involves 24 healthy participants. These subjects will consume alcohol or a placebo to establish a comparative baseline for impairment levels.
The primary outcome measure for the trial is lateral vehicular control, which assesses the driver's ability to maintain a steady lane position. Furthermore, clinicians will perform cognitive assessments and analyze biological samples to measure cannabinoid concentrations. Therefore, the study offers a comprehensive view of how therapeutic doses affect cognitive and motor skills. Additionally, these results will help clinicians in India and globally counsel patients more effectively regarding safe medication use.
This study benchmarks cannabis impairment against a 0.05% blood alcohol concentration. Consequently, researchers can determine if therapeutic THC doses cause impairment similar to legal alcohol limits.
The CAN-TRACK trial specifically studies patients with chronic pain to answer this question. It aims to clarify whether regular therapeutic use leads to significant impairment during real-world driving scenarios.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Arkell TR et al. Effects of prescribed medical cannabis and alcohol on real-world driving performance (CAN-TRACK): a study protocol for a two-phase trial. Trials. 2026 Feb 06. doi: 10.1186/s13063-026-09512-x. PMID: 41652433.
McCartney D, et al. Determining the magnitude and duration of driving impairment after cannabis use: A systematic review and meta-analysis of double-blind randomized controlled trials. Neurosci Biobehav Rev. 2021;124:189-204.
Ramaekers JG, et al. Effects of delta-9-tetrahydrocannabinol on driving performance and cognitive function. Psychopharmacology. 2020;237(12):3553-3564.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The CAN-TRACK trial is a two-phase study evaluating the effects of prescribed medical cannabis and alcohol on real-world driving performance and road safety...
7 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
